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Abstract
Background: Chlamydia trachomatis is one of the most disseminated human pathogens, for which no vaccine is available
yet. Understanding the impact of the host pressure on pathogen antigens is crucial, but so far it was only assessed for
highly-restricted geographic areas. We aimed to evaluate the evolutionary picture of the chlamydial key antigen (MOMP),
which is one of the leading multi-subunit vaccine candidates, in a worldwide basis.
Methodology/Principal Findings: Using genetics, molecular evolution methods and mathematical modelling, we analyzed
all MOMP sequences reported worldwide, composed by 5026 strains from 33 geographic regions of five continents. Overall,
35.9% of variants were detected. The evolutionary pattern of MOMP amino acid gains/losses was found to differ from the
remaining chromosome, reflecting the demanding constraints of this porin, adhesin and dominant antigen. Amino acid
changes were 4.3-fold more frequent in host-interacting domains (P,10212), specifically within B-cell epitopes (P,1025),
where 25% of them are at fixation (P,1025). According to the typical pathogen-host arms race, this rampant B-cell
antigenic variation likely represents neutralization escape mutants, as some mutations were previously shown to abrogate
neutralization of chlamydial infectivity in vitro. In contrast, T-cell clusters of diverse HLA specificities are under purifying
selection, suggesting a strategy that may lead to immune subversion. Moreover, several silent mutations are at fixation,
generating preferential codons that may influence expression, and may also reflect recombination-derived ‘hitchhiking-
effect’ from favourable nonsilent changes. Interestingly, the most prevalent C. trachomatis genotypes, E and F, showed a
mutation rate 22.3-fold lower than that of the remainder (P,10220), suggesting more fitted antigenic profiles.
Conclusions/Significance: Globally, the adaptive evolution of the C. trachomatis dominant antigen is likely driven by its
complex pathogenesis-related function and reflects distinct evolutionary antigenic scenarios that may benefit the
pathogen, and thus should be taking into account in the development of a MOMP-based vaccine.
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Introduction
Chlamydia trachomatis is an obligate intracellular pathogen that
causes ocular-genital infections in humans. Trachoma (chlamydial
genotypes A–C and Ba) is the world’s leading cause of preventable
blindness with special impact in resource-poor nations, which has
been recently placed on the WHO’s priority list for intervention
[1]. Also, the asymptomatic character of most genital chlamydial
infections (genotypes D–K, Da, Ia, Ja and L1–L3) makes this
pathogen the major cause of bacterial sexually transmitted
infections worldwide [2]. Thus, C. trachomatis constitute a major
public health problem, and the development of effective
preventive strategies, such as a vaccine, are urgently needed. So
far, vaccine attempts failed to provide broad coverage and
conferred limited protection [3,4].
One of the leading multi-subunit vaccine candidates is the C.
trachomatis major outer membrane protein (MOMP), coded by
ompA, whose variations underlie strain classification into sero-
groups (B, C and Intermediate) or genotypes [5]. It is the
dominant antigen with tenths of well-defined species and serovar-
specific epitopes, eliciting both the humoral and cellular immune
responses [3,6–9]. MOMP constitutes about 60% of the
membrane dry-weight [10] and is a trimer stable under reducing
conditions [11]. Each monomer is predicted to form a 16-stranded
b-barrel structure resembling a porin [12], where the four highly
variable domains (VDI to VDIV) of the protein are surface
exposed. Also, the charge properties of VDs support an adhesion
role for MOMP [13], both at the time of attachment to the host
cell as well as to the host inclusion membrane to interact with the
mitochondria and endoplasmatic reticulum [14,15]. Moreover,
this protein is likely an important virulence factor as it has been
demonstrated that subtle mutations may yield profound distinct
strain-specific neutralizing antibody responses in a nonhuman
primate trachoma model [16], and it presents an immune decoy
function by blocking the binding of broadly protective species-
common pan-neutralizing antibodies [17].
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It is believed that C. trachomatis evolution involved the loss of
huge portions of its genome upon becoming an obligate
intracellular parasite [18]. Subsequently, the evolutionary accu-
mulation of mutations and insertion/deletion (indel) events
resulted in the formation of pseudogenes [19,20], the phylogenetic
segregation of strains according to their cell-appetence [21,22],
and the generation of specific evolutionary pictures for heteroge-
neous loci categories [21]. Recently, a geographic-restricted study
showed an adaptation of the C. trachomatis key antigen to the host
immune pressure [23], shedding some lights about the MOMP
adaptive evolution. Here, we aimed to determine MOMP
evolutionary picture in a worldwide basis by using all available
ompA sequences reported in the literature, which totalize 5026
strains isolated in 33 distinct geographic regions dispersed by five
continents. We mapped MOMP positions that are more prone to
change as well as specific mutations in epitopes that are at fixation
around the globe. Globally, the adaptive evolution of the C.
trachomatis dominant antigen likely reflects its complex pathogen-
esis-related function as an adhesion, porin, and major antigen,
showing distinct evolutionary scenarios for B- and T-cell epitopes.
The worldwide coverage of this assessment is unprecedented to
date.
Results
Characterization of C. trachomatis specimens
A total of 5026 C. trachomatis strains isolated in 33 distinct
geographic regions from five continents were analyzed in this
worldwide survey. These encompassed all ompA genotypes with
exception of L3, which was not found. Genotype E was the most
prevalent type (30.0%), followed by genotypes F (12.9%), and L2
(9.8%). Globally, 1802 (35.9%) specimens were found to present
ompA variant sequences when compared to that of the respective
prototype strain (that define each ompA genotype), which have
been used worldwide as comparative-baseline since their isolation
up to 60 years ago (Table 1). Genotypes L2 and G presented the
highest number of ompA variant specimens (n = 462 and n= 309,
respectively), while genotypes E and F, which together represent
almost half (42.3%) of all analyzed specimens, were the least
variable, where only 83 out of 1464 E strains (5.6%) and 40 out of
640 F strains (6.3%) were variants. In fact, these two most
worldwide prevalent types showed an ompA mutation rate 22.3-fold
lower than that of the other genotypes (P,10220), which suggest
that the dominant antigenic profile of E and F MOMP may be
better fitted to deal with the host immune system, which
consequently may favor their ecological success.
The 1802 variant specimens constitute 234 distinct types of
genetic variants (i.e., with a distinct ompA mutational pattern that
may be shared by several strains), for which no insertion/deletion
or any trace of recombination event was found in ompA.
Supporting this, robust phylogenies (Figure 1) were observed with
maximum bootstrap support (97–100%) in the three main
branches corresponding to the traditional chlamydial serogroups.
In fact, nucleotide genetic distances among strains within the same
genotype did not exceed 0.7% (standard error, SE 0.2%). In
contrast to the other genotypes, most types of genetic variants for
the least variable genotype E are represented by a single specimen,
which suggests that the corresponding mutations are not being
fixed.
Worldwide ompA variability
Globally, a total of 511 variable sites (corresponding to the sum
of all mutations between each type of genetic variants and the
respective prototype strain) were found throughout ompA, where
56% of them occurred in VDs and 44% occurred in constant
domains (CDs). About 68% of mutations yielded amino acid
changes (with two thirds occurring in VDs), while ,32% resulted
in silent substitutions (with two thirds occurring in CDs). Figure 2
illustrates the most relevant variation found in MOMP for the 17
C. trachomatis genotypes, showing 70.3% (n= 359) of all variable
sites found in the ompA. One fifth of them were exhibited by same-
genotype strains isolated in two to 20 (for nonsynonymous
mutations) or $5 (for silent mutations) different geographic
Table 1. Description of the 17 baseline prototype strains representing the C. trachomatis genotypes.
Genotype/Strain Year Location Biological Sample GenBank Accession No.
A/Har13 1958 Egypt Conjunctiva NC007429
B/TW5 1959 Taiwan Conjunctiva AF304856
C/TW3 1959 Taiwan Conjunctiva AF352789
D/UW3 1965 Washington Cervix AE001338
Da/TW448 1985? Taiwan Conjunctiva X62921
E/Bour 1959 California Conjunctiva X52557
F/IC-Cal3 1960? California Conjunctiva X52080
G/UW57 1971 Washington Cervix AF063199
H/UW43 1965 Washington Cervix X16007
I/UW12 1966 Washington Urethra AF063200
Ia/IU4168 1987 Indiana Urethra AF063201
J/UW36 1971 Washington Cervix AF063202
Ja/IUA795 1986 n.a. Cervix AF063203
K/UW31 1973? Washington Cervix AF063204
L1/440 1968 California Lymph Nodes M36533
L2/434 1968 California Lymph Nodes M14738
L3/404 1967 California Lymph Nodes X55700
doi:10.1371/journal.pone.0013171.t001
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regions (Figure 2), which may indicate a fixation of these mutations
in those genotypes likely conferring them some structural or
antigenic advantage. For example, the VDII Ala-to-Thr change
occurring in the B-cell epitope 172AFVP175 [24] seems to become
fixed within genotype B, as it was exhibited by 137 out of the 157
B variant specimens from 18 distinct geographic regions (data not
shown). Moreover, of the 12 silent mutations that may be at
fixation (Figure 2), 75% of them generated synonymous codons
with high frequency usage in C. trachomatis [25]. For instance, for
genotype J, the CDII C-to-T third-position change in the low
frequent Asn codon AAC yielded the more frequent synonymous
codon AAT (that is used almost two times more often than AAC)
in 101 of the 113 (76%) J variant isolates from 10 distinct
geographic regions (data not shown). Curiously, this AAT codon is
conserved among all genotypes of B- and Intermediate-serogroups.
In general, considering the MOMP genetic variability observed
for all C. trachomatis genotypes, we found that 148 (37.3%) different
sites of the protein were already subject to amino acid alterations
(Figure 3). About 44% of the sites suffered mutations that occurred
simultaneously among strains from two to ten different genotypes.
Also, more than half of these ‘hotspot’ sites involved changes that
seem to be at fixation, and were found to occur 2.4-fold more
frequently within B-cell epitopes (P,1022). Altogether, these
results suggest that MOMP variability is not random as there are
protein sites that are more prone to change, likely due to fitness
advantages or simply to MOMP functional constraints.
Evaluation of selective pressure on MOMP
To examine the selective pressure acting on MOMP, only the
234 types of genetic variants together with the 17 prototype strains
were considered. This conservative approach avoids any bias
arising from the existence of an unequal number of specimens
represented by each type of genetic variant, resulting from the
considerably different population sizes of the studies performed to
date. The analysis of the molecular evolution of whole ompA
sequence for all the 251 taxa showed a global mean ratio of
synonymous (dS) to nonsynonymous (dN) substitution rates (dN/
dS) of 0.26 (SE 0.03). The analysis per genotype showed dN/dS
values .1 for genotypes A, G, Ia, and K (data not shown),
suggesting a phenomenon of positive selection. However, due to
the nondiscrimination of codons with distinct evolutionary
signatures, this global dN/dS statistics may generate artifactual
trends of synonymous and nonsynonymous rate variation when
very few amino acids are under positive selection.
In order to investigate if any portion of ompA is undergoing strong
selection as well as which regions are not bound by strong functional
constraints, a codon-based sliding-window analysis was also used to
evaluate dN/dS throughout the entire gene. Although ompA showed
a general trend of dN/dS,1, three distinct gene regions were
identified with a statistically significant ratio.1 (Figure 4A),
indicating that they are likely under positive selection. Interestingly,
these regions are precisely located inside the VDI, VDII and VDIV,
which (together with VDIII) showed a global nonsynonymous rate
4.3-fold higher than that of the CDs (P,10212), suggesting a
targeted amino acid variability in MOMP surface-exposed
domains. In support of this, several putative positively selected
codons were found within the VDII 165TQSSNF170 epitope or
within a VDIV region containing multiple core B-cell epitopes for
genotypes Ia and E, respectively. Almost all of these codons suffered
nonsynonymous mutations that may lead to disruption of those
epitopes in some E and Ia genetic variants. For all genotypes, almost
all of the dN peaks observed occurred within or adjacent to well-
defined MOMP epitopes, and also involved mutations that seem to
become fixed among same-genotype strains (Figure 4B). Globally, it
is possible that these results of positively selected regions may clearly
be underestimated. In fact, it was recently demonstrated that for
short time-scale models, the anticipated signature of adaptive
evolution (dN/dS.1) is violated because dN/dS,1 was found to
occur under both negative and positive selection [26].
Is variability in MOMP a host evasion strategy?
The mutational trend in MOMP antigenic regions was
investigated taking into account all B- and T-cell [cytotoxic T
lymphocyte (CTL) and T helper (Th)] epitopes already described
in the literature for the corresponding prototype strains (Figure
S1). For this analysis, only minimal epitopes fully mapped were
considered in order to avoid any bias arising from an
overrepresentation of MOMP antigenic regions. Overall, of the
total 511 mutations, 176 (34.4%) were found to occur within or
adjacent to MOMP B- and T-cell epitopes with species, serogroup
or genotype specificities. From these, 88.1% solely involved B-cell
epitopes, which is statistically significant as they encompass only
about 19% of the total protein length (P,10215). We observed
that 82.6% of them resulted in amino acid replacements, yielding
a global nonsynonymous mutation rate almost threefold higher for
these B-cell antigenic regions than for the rest of the ompA gene
(P,1025), which suggests targeted amino acid variability. More,
25% of these mutations were found to become worldwide fixed
within some genotypes (P,1025) (Figure 2). Also, some of them
were previously shown to abrogate monoclonal antibody binding
and neutralization of the infectivity of several prototype and/or
variant strains in vitro [7,8,27]. For instance, the VDIV Ala-to-Thr
change observed for genotypes D and Da was previously shown to
prevent the antibody binding at the serogroup B 323IAGAG327
epitope for the known genovariant D2 [27]. This mutation seems
to become fixed within genotypes D and Da, as it was found in
strains from five and eight different geographic regions, respec-
Figure 1. ompA phylogeny of the 251 C. trachomatis genetic
variants. The represented tree was generated using the Neighbour-
Joining method (with Kimura 2-Parameter model) but similar topologies
were obtained with other methodologies (see Methods). Genotypes are
represented in different colors. Thickness of solid triangles is
proportional to the number of taxa from each genotype (n). The mean
genetic diversity within each ompA genotype-population (p) is shown.
The ompA sequence from C. muridarum strain MoPn (NC002620) was
used to root the tree. Bootstrap values (1,000 replicates) are shown next
to the branch nodes.
doi:10.1371/journal.pone.0013171.g001
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tively (Figure 2). Moreover, the VDI Ala-to-Val change found in
25% of the C variant strains from three distinct geographic regions
was shown to prevent antibody binding to the 92DVAGL96 epitope
(Figure 2), which is known to be highly intolerant to substitution
[8]. Although the impact of these changes also depends on the
epitope conformation that may vary among genotypes, the
existence of such disrupting mutations in MOMP B-cell epitopes
clearly evidence a C. trachomatis strategy to evade recognition and
neutralization by host antibodies, allowing thereby the infection to
evolve.
Of the 21 mutations occurred within or adjacent to T-cell
antigenic regions, 66.7% involved clusters of CTL and Th
epitopes. For example, several nonsynonymous mutations exhib-
ited by D, Da, G, H, Ia and J specimens were found within the
CDIV species-specific cluster of five human leukocyte antigen
(HLA) class I-restricted minimal CTL epitopes [28] that
superimposes (except for G) a cluster of at least six HLA class
II-restricted core Th epitopes [29] (Figure 2). Another interesting
example occurred for genotype E, where four nonsynonymous
mutations were found within the E-specific CTL epitope
177SLDQSVVEL185 [28] that overlaps an E-specific Th-epitope-
containing peptide [29,30] and is adjacent to three well-defined B-
cell core epitopes [7] (Figure 2A). Curiously, none of the above
cited mutations seems to become fixed as they were exhibited
solely by one strain of a single genotype or were restricted to a
single geographic region, suggesting their nonfixation. In support
of this, we found a statistically significant low dN/dS value for
MOMP CDIV T-cell epitope region suggestive of purifying
selection (Figure 4A).
Evolutionary dynamics of amino acid gains and losses
Considering the above evidenced strong selective pressure
acting on this dominant chlamydial antigen, we examined the
mutational trend of amino acid gains and losses in MOMP
evolution. Therefore, for each prototype strain, a mathematical
approach was used to estimate the ‘expected’ frequency of each
amino acid considering all possible single nucleotide polymor-
phisms (SNPs) for each codon position. Depending on genotype,
about 3550 different SNPs may randomly occur in ompA.
Curiously, no significant differences were found for the amino
acid frequencies calculated using different overall mean ratios of
transitions rate to transversions rate (R). The evolution of the
amino acid composition of MOMP was determined by comparing
these ‘expected’ frequencies (mathematical approach) with the
ones ‘observed’ for all types of genetic variants isolated worldwide
(Figure 5A). The amino acids Ala, Val, Thr and Ser were the most
accrued in all scenarios, while Trp and Met revealed the lowest
frequencies. However, frequency discrepancies were found for
Met, Phe Tyr and Cys, suggesting that evolution of amino acid
composition in MOMP may be ruled by intrinsic trends that
emerge from specific mutational and selective pressures. For
example, despite Met is one of the less frequent amino acids, it is
being acquired up to 4 times less than the mathematically
expected. Also, the observed frequencies for Phe, Tyr and Cys are
about 2 times less than the expected. Interestingly, these amino
acids were found to belong to the top five ‘gainers’ (His, Arg, Pro,
Tyr and Val) or ‘losers’ (Met, Trp, Phe, Cys and Asp) among the
worldwide genetic variants, as they presented the highest or the
lowest ratios of create/remove substitutions and thus are being
evolutionary accrued or lost in MOMP, respectively (Figure 5B).
For instance, for each His that is lost, nine are being acquired
(P=0.007), while for each Met accrued, 10 are being removed
(P=0.01). In contrast to what is traditionally assumed, this
nonrandom mutational dynamics suggests that the amino acid
composition of MOMP is far from a total equilibrium. Although
the impact of these mutational trends in MOMP evolution is not
known, the gain or loss of certain amino acids were already shown
to influence the structure of several bacterial porins [12]. In
agreement with this, we found that about two thirds of the 83
substitutions involving the negatively charged residues Asp and
Glu occurred in MOMP external loops, where they are known to
be involved in the binding to the lipopolysaccharide [31].
Bioinformatically, these substitutions did not reveal significant
differences in protein chemical properties, suggesting that only
minor porin structural alterations are expected on behalf of
adaptive environmental changes. Also interesting was the
preservation of the seven Cys residues, which are 100% conserved
among all C. trachomatis genotypes. More, the apparent fixation of
the CDI Val-to-Cys change in all B variant specimens (isolated
from 12 distinct geographic regions) indicates that this Cys residue,
which is conserved among the remaining genotypes, is important
at this specific protein position. Considering their ability to form
Figure 3. Topology sketch of MOMP mutational hotspots. VDs
are presented in red, while CDs are in black. Circles represent amino
acids located at external loops and periplasmic turns, while squares
represent amino acids of the transmembrane b-strands (based on refs
[12,35]). Sites of the protein that were already subject to amino acid
alterations are fulfilled in blue. Protein sites that were simultaneously
mutated among strains from two to ten different genotypes
(mutational ‘hotspots’) are marked with a cross.
doi:10.1371/journal.pone.0013171.g003
Figure 2. Worldwide mutational pattern of MOMP. Panels (A), (B), and (C) represent protein alignments of prototype strains according to
serogroup B, Intermediate, and C, respectively. Amino acid changes that naturally occur among prototype strains are in grey characters (they do not
represent changes among variant specimens and the respective prototype strains). Mutations resulting from the comparison between the 5026
strains isolated in 33 different geographic regions from five continents and the respective prototype strain are highlighted in different colors,
corresponding to dissimilar degrees of evolutionary fixation. Green, orange and red represent amino acid changes occurring in strains isolated in a
single, 2–4, and $5 geographic regions, respectively. Only silent mutations that occurred in strains isolated in $5 geographic regions are shown
(highlighted in grey). Well-defined B-cell (blue), Th-cell (purple) and CTL (black) antigenic regions are underlined. Degenerated variable sites are
marked with an asterisk.
doi:10.1371/journal.pone.0013171.g002
Mutational Trends in Chlamydia
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13171
intra- and intermolecular disulfide bonds, the conservation of a
higher number of Cys residues in MOMP reinforces their role in
maintaining the membrane structural integrity of a pathogen that
lacks the typical peptidoglycan layer found in other gram-negative
bacteria [32].
Discussion
The detailed understanding of the evolutionary pathway of
pathogen’s antigens is of the utmost importance, especially when
no efficacious preventive strategies (such as a vaccine) are available
Figure 4. Selective pressure acting on ompA. (A) Ratio of dN/dS throughout ompA. dN/dS was estimated over a nucleotide sliding window
(window size = 15; step size = 3), considering the 234 types of genetic variants and the 17 prototype strains. VDs are shown in horizontal red lines,
while dashed line represents the traditional cut-off for neutral evolution. Only P-values showing statistical significance are shown. For positive and
purifying selection P-values are displayed above and below the cut-off dashed line, respectively. Region containing MOMP CDIV species-specific
cluster of five CTL and six Th epitopes (see text) is marked with (*). (B) dN values throughout ompA for genotype A (here, as an example). Calculations
were performed over a sliding window (window size = 15; step size = 3), considering all types of genetic variants of genotype A. VDs (red boxes)
display a global nonsynonymous rate 4.3-fold higher than that of the CDs (P,10212). dN peaks involving mutations occurring within/adjacent to B-
cell epitopes and/or mutations that are likely at fixation in this genotype are marked with (*) and ({), respectively.
doi:10.1371/journal.pone.0013171.g004
Figure 5. Evolutionary dynamics of amino acid gains and losses. (A) Ratio between the amino acid ‘expected’ frequency (calculated by
mathematical modeling using two different overall mean R values, 1.2 (upper row) and 3.6 (lower row) – see methods) and the ‘observed’ frequency
for the 251 genetic variants. Normalized ratio intervals (log2) are color-coded. For Trp, which was the unique amino acid that was never created from
the total 511 variable sites found in ompA, the ‘observed’ frequency was calculated by determining the mid-point of the respective exact 95%
confidence interval using the ration between the F and Binomial distribution [57]. (B) Empirical data showing the ratio of created/removed amino acid
substitutions that were ‘observed’ among the 251 genetic variants. Normalized ratio intervals (log2) are color-coded, and each amino acid is shown
below to the correspondent interval. Statistical significance (P#0.02) was found for the amino acids marked with an asterisk. For panels (A) and (B),
logarithmic transformation of the ratios is required for symmetrical distribution of the data around zero.
doi:10.1371/journal.pone.0013171.g005
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yet. In this worldwide survey, we intended to provide a more
complete picture of the mutational trends of the C. trachomatis
leading multi-subunit vaccine candidate.
Contrarily to other chlamydial loci, where polymorphism
reflects genotype’s adaptation to different biological niches and
ecological success [21], no compelling association was established
at molecular, phylogenetic or immunological level for MOMP.
Our data revealed that amino acid composition of MOMP is far
from a detailed equilibrium as certain residues seem to be
consistently accrued (His, Arg, Pro, Tyr and Val) or lost (Met, Trp,
Phe, Cys and Asp) in protein evolution (Figure 5B). This MOMP
substitution pattern diverge from the ongoing changes of amino
acid frequencies of the remaining C. trachomatis chromosome,
where Cys, Phe, Arg, Met and His as well as Lys, Leu, Glu Pro
and Tyr appear as the five strong gainers and losers, respectively
[33]. More, the frequency fluctuations relative to mathematical
modelling (Figure 5A) corroborate the singular nature of this key
antigen, ruled out by specific mutational and selective pressures.
They likely drive protein evolution towards better antigenic fitness,
as amino acid changes were almost threefold more frequent in B-
cell antigenic regions (with 25% likely at fixation worldwide) than
in the remaining protein (P,1025), similar to that previously
found in Portuguese isolates [23]. Although the in vivo implications
of these alterations in MOMP are still unknown, some of them
were previously shown to prevent recognition and neutralization
by host antibodies in vitro [7,8,27]. Moreover, this immunodomi-
nant protein may be strategically used as reservoir for antigenic
variability in a chlamydial decoy-like host immune evasion, as
MOMP was found to block the binding of more broadly protective
species-common pan-neutralizing antibodies, which have been
suggested as potential alternatives for a chlamydial vaccine [17].
It has been argued that both the immunogenicity and adhesion
role of MOMP may also depend on the protein native
conformation (nMOMP) (still unknown) [34]. Consonant with
this, we have found a nonrandom mutational dynamics involving
amino acids (ex. Asp, Glu and Cys) that are thought to be critical
for the nMOMP structure [12,35], which may consequently affect
the conformation and immunoaccessibility of antigenic regions.
Recently, by using a nonhuman primate trachoma model, Kari
et al. [16] found that immunization with the trimeric nMOMP
yielded striking different neutralizing antibody titers against two
genotype A strains that differ solely by four amino acids in
MOMP. Although none of these changes fall within known B-cell
epitopes, it suggests that any apparently minor alteration may
influence the nMOMP structure [16]. Accordingly, we speculate
that the 18 nonsilent alterations occurring outside known VD
antigenic regions that seem to be at fixation worldwide (Figure 2),
may have important conformational immunogenic implications in
nMOMP, with likely more impact in exposed B-cell epitopes than
in the transmembrane linear T-cell epitopes.
It has been shown that humoral immune responses facilitate
antibody-dependent cellular cytotoxicity and, most importantly,
boost the induction of an optimal memory Th1 response through
rapid uptake, processing and presentation of antigens [36]. Thus,
it is expected that evolutionary fixation of mutations in MOMP B-
cell antigenic regions may have pathological consequences at the
concertedly humoral and cellular immune responses, which may
contribute to chlamydial recurrence or persistence, as previously
demonstrated for several virus [37]. In MOMP, CTL and Th
epitope clusters of diverse HLA specificities are localized in
nonpositively selected CDs (Figure 4), which could apparently
constitute promising components for a successful multi-subunit
vaccine, enabling widespread protective immunization for a
genetically diverse human population [6]. An interesting candidate
is the MOMP CDIV species-specific cluster of five CTL and six
Th epitopes binding three HLA class I and four HLA class II
allotypes [28,29], in which variability is thought to disrupt vital
protein functions and greatly reduce pathogen fitness [6]. This is
supported by our data as none of the nonsynonymous mutations
occurred in these cluster epitopes seems to become fixed (as shown
by the low dN/dS value for this region – see Figure 4A). However,
this lack of antigenic variation on these MOMP T-cell clusters
might indicate a pathogen’s evolutionary mechanism that may
lead to immune subversion, analogous to the one found for
Salmonella enterica serovar Typhimurium [38] and Mycobacterium
tuberculosis [39], which show a similar intracellular life-style. It is
believed that both recognition and consequent cellular immune
response to these epitopes might actually provide a net benefit to
the pathogen, while may be detrimental to the host [39], as they
may maximize the likelihood of pathogen’s transmission or
persistence. Reinforcing this, it has been shown that MOMP
alone is unable to elicit a Th1 response (predominantly by IFN-c
secretion) sufficiently strong to resolve chlamydial infection and
confer protective immunity [4]. Thus, it could be speculated that
this pathogen may have developed ways of avoiding IFN-c
mediated effectors, clearly compromising the Th1-way of reaching
effective protection, which seems mandatory for a vaccine against
Chlamydia.
Intriguingly, a high level of conservation of MOMP seems to be
associated with a higher ecological success, as we have previously
suggested [23]. Indeed, the two most prevalent C. trachomatis
genotypes, E and F, showed an ompA mutation rate 22.3-fold lower
than that of the other genotypes (P,10220). As the existence of
distinct antigenic profiles among genital genotypes was previously
demonstrated [29,30,40], we speculate that the about 12%
MOMP amino acid differences among genotypes [21] may confer
E and F antigenic profiles better fitted to deal with the host
immune system, which would be less prone to change in the light
of the Darwinian evolutionary theory. Considering the uniqueness
of the chromosomal genetic make-up and evolutionary course of
these two genotypes [21], we speculate that E/F specific virulence
factors may also contribute for their ecological success, which does
not seem to be correlated with the intracellular multiplication rate
[41].
In C. trachomatis, no weight has usually been given to silent
mutations that take place in ompA, although they were found to
constitute 49.3% and 18.5% of all mutations observed in CDs and
VDs, respectively, and some of them seem to be fixed worldwide
within some genotypes (Figure 2). However, it has been
demonstrated that the generation of synonymous codons may
influence the mRNA structure [42], the translation efficiency [43],
and the protein folding and tertiary structure [44]. For example, it
was shown that some highly expressed genes of E. coli [45], S.
cerevisiae [46] and B. subtilis [47] have a strong preference for
codons recognized by the most abundant tRNA species, which
promotes translational efficiency. Similarly, we have found that
75% of all silent mutations that are likely at evolutionary fixation
resulted in synonymous codons with high frequency usage in C.
trachomatis [25]. This ‘‘travelling without moving’’ phenomenon
[48] permit the immediate MOMP adaptive landscape to differ
among strains without changing its sequence, function or fitness,
allowing the protein to modify its evolutionary pathway according
to environmental and host immune pressures.
Another interesting but cautious consideration about beneficial
or deleterious mutations in ompA relates to the ‘‘hitchhiking effect’’,
where an evolutionarily neutral or even deleterious mutation may
spread through the population due to its proximity to a beneficial
mutation (being dragged in the same recombinant fragment) [49].
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This effect may be expected to occur in ompA due to its well-
described recombinant character [50,51], and it may explain the
high frequency of some apparent neutral mutations, such as the
seven silent mutations in close proximity to three potential
advantageous nonsynonymous mutations in CDI of numerous B
variant specimens from five to 11 geographic regions (Figure 2).
One of these favourable mutations was found to provide all
B variant specimens with a Cys residue, which is conserved among
the remaining C. trachomatis genotypes and thus may play an
important role in maintaining the membrane structural
integrity.
Although the extant variant specimens reported in this
worldwide review may have suffered the effects of the immune
system of hundreds of different hosts and may represent several
thousands of bacterial generations, still, they constitute a flash in
the ,100 million-year chlamydial evolution [52]. Even with this
extremely short time-scale (about six decades), our results clearly
evidence the existence of intrinsic mutational trends for MOMP, a
crucial antigen, adhesin, and porin. We observed the existence of
distinct evolutionary scenarios in MOMP B- and T-cell epitopes
that may benefit to the pathogen. Despite the hypothetical
accumulation of some mutations in prototype strains (that were
here used as ‘‘baselines’’ for the clinical variants) due to in vitro
passage (which was never demonstrated for Chlamydia), there is no
immune pressure associated with the cell-lines used for their
passage. Thus, even if some mutations occur in laboratory
prototype strains they are driven by genetic drift, and it is not
credible that they could mask the statistically supported B-cell
targeted fixation of mutations observed worldwide for clinical
strains. This hitherto unrevealed extensive variation in B-cell
antigenic regions suggests a still undisclosed complex scenario of
dynamic antigenic profiles for this unavoidable pathogen’s
antigen, likely representing new neutralization escape mutants
that continue to co-evolve with the human host. Together with the
apparent conserved T-cell scenario, they likely constitute an
obstacle for the development of an efficacious MOMP-based
vaccine, whose success will require the presence of other protective
antigens and/or the identification of novel broadly cross-reacting
conformational-dependent MOMP neutralizing antibodies, whose
specificity and protective function are not affected by this
mutational scenario.
Materials and Methods
Study population
An exhaustive and complete literature search was performed to
look for all sequence-based MOMP published surveys containing
both variant and nonvariant ompA sequences compared to the
respective prototype strains. In general, the study population from
the 56 surveys performed to date, encompassed patients attending
to general practice, family planning, obstetrics, gynaecology and
STD clinics, as well as individuals from specific and restrict
communities (such as homosexual networks or resource-poor
villages where LGV and trachoma are relevant, respectively). To
avoid bias potentially arising from the duplication of specimens,
the following precautions were taken: i) specimens collected from
sexual partners during the same year were excluded; and ii) for
longitudinal studies where more than one sample can be collected
from the same patient, only one stage of the study was considered
as it would be impossible to distinguish if samples of further stages
were from re-infection or a merely persistence episode. To our
knowledge, none of the strains was propagated in cell culture after
a plaque assay (or limiting dilution techniques) in order to obtain
clones. Accordingly, one cannot tell whether the determined ompA
genotype refers to a single clone or to the predominant clone (if a
mixed infection occurred).
For genotype comparisons, the traditional prototype strains
representing all C. trachomatis serovars were used as baseline.
Considering that for some prototype strains inconsistencies were
observed among ompA sequences that were obtained in the 80s and
the beginning of 2000 (when automated sequencing by capillary
electrophoresis started), only the later were selected because of
their likely higher reliability. However, the possibility of these
inconsistencies could also be due to different clones of the same
prototype strain cannot be discarded. Therefore, the prototype
strains used in this study are described in Table 1. Although the
use of Ba/Apache2 as reference strain is consensual, it was
considered as a B-variant in the present study due to its closer
proximity to the prototype B/TW5 than some well-known B
strains as well as to its similar ompA mutational pattern with several
previously classified B-variant strains, which makes any B/Ba-
serovar distinction, in our opinion, inaccurate. Moreover, some
specimens reported in the literature as D-, I-, and J-variants were
found to be identical to prototype strains Da, Ia and Ja, and thus
were not considered as variants in the present study.
Genomic and phylogenetic analyses
Genomic and phylogenetic analyses were performed as
previously described [23]. Briefly, for each ompA genotype, the
MEGA 4.0.2 software (http://www.megasoftware.net) was used to
produce alignments, to create matrices of pairwise comparisons, to
estimate the number of variable sites, to compute overall mean
genetic distances within and between serogroups, and to generate
phylogenies at the nucleotide level. For the later, both the
Neighbor-Joining method (with Kimura 2-Parameter and Ta-
mura-Nei models) and the Maximum Parsimony method (using
the max-min branch-and-bound algorithm) were used as previ-
ously described [21]. As more than two-thirds of the mutations are
nonsynonymous, these analyses were repeated at the protein level
to check the existence of ambiguities. In addition, the mean
genetic diversity within each ompA genotype-population (p) was
estimated using the Maximum Composite Likelihood method.
Considering that many genes display a nonrandom usage of
synonymous codons for specific amino acids, the SWAAP 1.0.3
software (http://www.bacteriamuseum.org/SWAAP/SwaapPage.
htm) was used to compute the codon frequency and the relative
synonymous codon usage [46] for all genotypes. Because of the
different lengths of the sequences, the pairwise-deletion option was
chosen to remove all sites containing missing data or alignment
gaps, only when the need arose and not prior to the analyses.
Standard error estimates were obtained by a bootstrap procedure
(1,000 replicates).
Since recombination is a mechanism of genetic variability,
the SimPlot/BootScan software (http://sray.med.som.jhmi.edu/
SCRoftware/) was used to evaluate the existence of any recom-
bination event in ompA of each specimen, as previously described
[53].
Analysis of molecular evolution
For each ompA genotype, the Nei-Gojobori method [54] of
MEGA was used to calculate the overall mean of dS and dN, as
previously described [55]. The p-distance model was used to
normalize the computed differences against the number of
potential synonymous and nonsynonymous sites. dS and dN were
also evaluated over a sliding window (window size = 15; step
size = 3) using the Nei-Gojobori method of the SWAAP. In order
to evaluate the statistical significance of the operating selective
pressure on MOMP specific domains, a codon-based Z-test of
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selection was performed to calculate the probability (95%
confidence interval) for rejecting the null hypothesis of strict-
neutrality (dN=dS) in favor of the positive (dN.dS) or purifying
selection (dN,dS). An exhaustive evaluation of the exact codons
under positive selection, using a more conservative and powerful
bioinformatic approach (maximum likelihood analyses), would
required the knowledge of all nonvariant specimens circulating
worldwide, which is unfeasible as studies involving solely
nonvariant specimens were not included in the present survey.
Since estimation of the ratio of transitions rate (Ts) to
transversions rate (Tv) provides insight into the process of
molecular evolution of a locus, the Tamura 3-Parameter method
[56] of MEGA was used to compute the overall mean of Ts/Tv
ratio (R) for all examined ompA sequences, while SWAAP was used
to evaluate R over a sliding window (window size = 60; step
size = 1), in order to identify gene regions in which functional
constraints are tolerated.
Analysis of protein features
To shed some light on the putative impact of each mutation on
MOMP, a comparative analysis of the protein sequences of all
variant and prototype strains was performed using the Protean
program of LaserGene (DNASTAR). Basically, the following
protein features were evaluated: charge density, secondary
structure, hydropathy, antigenicity, amphiphilicity, surface prob-
ability and flexibility. We used a sliding window of a specified
range of amino acids with the default parameters of each method,
as previously described [23].
Mathematical modelling
To examine the mutational trend of amino acid composition in
MOMP evolution, we used the ompA sequences of prototype
strains as baseline. We developed a mathematical approach to
estimate the ‘expected’ frequency of each amino acid considering
all possible SNPs for each position of the ,397 ompA triplets.
Depending on genotype, the novel triplets (ti) were determined
according to the distribution:
ti,wið Þ, i~1,    ,N
where wi represents the relative weight of each type of SNP. This
correction was performed because transitions typically occur in
nature much more often than transversions. For comparative
purposes, two different overall mean R values were used: one
relative to ompA (R= 1.2) and the other relative to ,50 loci of the
C. trachomatis chromosome (R= 3.6) [21]. Thus, for each possible
transition, it was assigned a relative weight of 1.2 or 3.6, while a
weight of 1 was assigned for all possible transversions. All amino
acids (aj ) resulting from the novel triplets generated, were
determined according to the following distribution:
aj ,sj
 
, j~1,    ,n
where each j represents the set of indices Ij~i1j ,i2j ,    ,ikj of all
triplets ti,wið Þ that code a certain amino acid, and
sj~
X
i[Ij
wi
represents the relative weight of each novel amino acid.
Considering that one amino acid may be encoded by several
synonymous triplets, the relative weight of each amino acid was
calculated by summing the weights of all same-amino acid triplets.
The final ‘expected’ frequency for each amino acid was calculated
according to the formula:
f aj
 
~
sj
Pn
l~1
sl
All calculations were performed using the free software environ-
ment for statistical computing and graphics R (http://www.r-
project.org/).
Statistic analyses
All statistics was performed using the SPSS Base version 15.0
(SPSS Inc. Chicago) in order to estimate the P values by Fisher’s
exact test as well as the odds ratios with a 95% confidence interval.
Supporting Information
Figure S1 MOMP antigenic regions. Outline of all B- and T-cell
core epitopes mapped for the 17 baseline prototype strains
representing the C. trachomatis genotypes.
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